



## WHY RIC?

RIC stands as a trusted and reliable source, offering the latest insights into cutting-edge REMS (Risk Evaluation and Mitigation Strategies) issues. Our consortium membership is comprised of drug and biopharmaceutical companies, as well as REMS program service providers, that are building a bridge for open communication and collaboration among many stakeholders, including our membership, healthcare community members, and FDA.

We unite industry stakeholders in a collective effort to address challenges, sharing invaluable experiences and best practices to guide your REMS programs. By joining RIC, you gain the opportunity to network and build lasting relationships with REMS industry professionals. Most importantly, you become an active contributor to advancing the REMS industry, making a significant impact on the field.

## BENEFITS AS A RIC MEMBER



**Contribute to REMS industry innovation**



**Network with REMS industry professionals at programs like the RIC Annual Meeting.**



**Exclusive knowledge-sharing opportunities**



**Opportunity to help develop leading-edge REMS education**

## HAVE YOUR VOICE HEARD THROUGH RIC WORKING GROUPS

### BEST PRACTICES

Leverage industry experience to suggest ways to streamline REMS program elements and enhance efficiencies for stakeholders.

### COMMUNICATIONS & MARKETING

Conducts qualitative review and feedback for materials produced by all working groups. Develops RIC communications plan, oversight of RIC branding/messaging, and identifies topics for white papers and supports publication.

### EDUCATION/CERTIFICATION

Develops educational resources and RIC credentialing programs for various stakeholders, which includes the development of core curriculum and ancillary training modules.

### FDA INTERACTIONS

Seeks to engage with FDA by responding to FDA outreach on REMS-related initiatives and preparing recommendations for FDA on ideas generated by working groups and task forces.

### VENDOR, INNOVATION & TECHNOLOGY

Explores ways to increase vendor capabilities. Identifies tactics to spur innovation and technology improvement.

# RIC LEADERSHIP



**Kevin Holman, MBA, RAC**  
RIC BOARD CHAIR  
Johnson & Johnson  
Innovative Medicine



**Kishore Gopu, MS, MBA**  
RIC BOARD VICE-CHAIR  
Teva Pharmaceuticals



**Kal Elhoregy, RPh, PA**  
RIC BOARD TREASURER  
Communications &  
Marketing Working Group Lead  
Amneal Pharmaceuticals



**Michael Cheung, DHSc, MS**  
RIC BOARD SECRETARY  
Bristol-Myers Squibb



**Ron Selders**  
RIC BOARD MEMBER  
Viartis

## FOUNDING MEMBER COMPANIES

Amneal Pharmaceuticals  
Bristol-Myers Squibb  
The Janssen Pharmaceutical Companies of  
Johnson & Johnson  
Jazz Pharmaceuticals  
Teva Pharmaceuticals  
Viartis



**ric**  
REMS Industry Consortium®  
Innovating Patient Safety. Mitigating Risk.

1120 Route 73, Suite 200  
Mount Laurel, NJ 08054

856.380.6894 | info@remsconsortium.org  
[remsconsortium.org](http://remsconsortium.org)



## JOIN LEADERS IN REMS

Aimmune Therapeutics,  
a Nestle Health Sciences  
Company

Alexion - Astra Zeneca  
Rare Disease Unit  
Amneal Pharmaceuticals  
Apellis Pharmaceuticals, Inc.  
Apotex

Ascend Laboratories LLC,  
a subsidiary of Alkerm  
Laboratories Ltd

Axian Consulting Ltd  
BioMarin

Bristol Myers Squibb  
Buchanan

Chinook Therapeutics, Inc.  
Compliance Architects LLC  
Endo Pharmaceuticals

Gilead Sciences  
GSK

Hikma Pharmaceuticals  
USA Inc.

Invariant LLC

Janssen

Jazz Pharmaceuticals

Mayne Pharma

Metis Consulting  
Services, Inc.

North Highland

Pfizer Inc.

Quandary Peak  
Research, Inc.

Sandoz

Sanofi

Shephard Safety Services  
at Two Labs

Sun Pharma

Syneos Health

Takeda

Tasman Pharma Inc.

Teva Pharmaceuticals

United BioSource LLC

Viartis

Zydus Pharmaceuticals  
USA Inc.



**ric**  
REMS Industry Consortium®  
Innovating Patient Safety. Mitigating Risk.

*Innovating  
Patient Safety.  
Mitigating Risk.*

# BECOME A LEADER IN REMS

**Join the REMS Industry  
Consortium today!**